Arturo Molina MD - 26 Nov 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Medical Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Issuer symbol
PTGX
Transactions as of
26 Nov 2024
Net transactions value
-$1,160,909
Form type
4
Filing time
27 Nov 2024, 19:11:13 UTC
Previous filing
19 Nov 2024
Next filing
06 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $44,453 +5,529 +12% $8.04 51,973 26 Nov 2024 Direct
transaction PTGX Common Stock Sale $252,122 -5,529 -11% $45.60 46,444 26 Nov 2024 Direct F1
transaction PTGX Common Stock Options Exercise $80,400 +10,000 +22% $8.04 56,444 27 Nov 2024 Direct
transaction PTGX Common Stock Sale $445,000 -10,000 -18% $44.50 46,444 27 Nov 2024 Direct F2
transaction PTGX Common Stock Options Exercise $128,640 +16,000 +34% $8.04 62,444 27 Nov 2024 Direct
transaction PTGX Common Stock Sale $717,280 -16,000 -26% $44.83 46,444 27 Nov 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -5,529 -4.3% $0.000000 121,971 26 Nov 2024 Common Stock 5,529 $8.04 Direct F4
transaction PTGX Stock Option (right to buy) Options Exercise $0 -10,000 -8.2% $0.000000 111,971 27 Nov 2024 Common Stock 10,000 $8.04 Direct F4
transaction PTGX Stock Option (right to buy) Options Exercise $0 -16,000 -14% $0.000000 95,971 27 Nov 2024 Common Stock 16,000 $8.04 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.